Volume: 4 Issue: 3
Year: 2016, Page: 32-38,
Introduction: Every time a drug is administered with any other prescription medicine, OTC products, herbs or even food we expose ourselves to the risk of a potentially dangerous interaction.A drug interaction occurs when the pharmacological effects of the object drug alters the intensity of the precipitant drug. Whenever two or more drugs are taken concurrently there is a chance of an interaction among the drugs that could manifest as an increase or decrease in their effectiveness or an adverse reaction or a totally new side effect that is not seen with either drug alone.
Materials and Methods :The study was done on male Sprague dawley rats, divided into 5 groups each having at least six animals.The groups were initially treated with carbamazepine at different doses for two weeks. Then all the groups were administered orally with a dose of 10 mg/kg of atorvastatin.Blood was collected from retro orbital plexus at 0, 1, 2, 4, 6,8,10 and 12 h after oral administration of atorvastatin and then subjected for analysis.
Results:The influence of carbamazepine on the pharmacokinetics of atorvastatin is decrease in Cmax, bioavailability and T1/2 indyslipidemic rats.
Conclusion:From the present investigation it is shown that the carbamazepine having considerable inducing effect on atorvastatin. The decreased bioavailability of atorvastatin in the study might be attributed to the induction of CYP-3A4 by carbamazepine. It might be true that, concurrent administration of the atorvastatin and carbamazepine could lead to alternations in the concentrations of either drug as both of them are substrates for CYP-3A4.
Keywords: Carbamazepine, Atorvastatin, Male Sprague dawley rats, dyslipidemia.
1. H. M. Lal, U. Lal. Drug Interactions - Mechanisms and Clinical Implications Medicine Update 2008;Vol. 18, chapter 89: 674-689.
2. Jennifer Martin, and Michael Fay, Cytochrome P450 drug interactions: are they clinically relevant? Australian Prescriber 2001; Vol. 24 No. 1:10-12.
3. Michael Sinz, Gillian Wallace, and JasminderSahi. Current Industrial Practices in Assessing CYP450 Enzyme Induction: Preclinical and Clinical, American Association of Pharmaceutical Scientists journal. June 2008; Vol. 10, No. 2: 391-398.
4. M. Ucar, M. Neuvonen, H. Luurila, R. Dahlqvist, P. J. Neuvonen, T. Mondale, Carbamazepine markedly reduces serum concentrations of simvastatin and simvastatin acid Pharmacokinetics and Disposition. European Journal of Clinical Pharmacology, February 2004; Volume 59, Issue 12: 879-882.
5. M. Srinivas, A.Annapurna and YelluNarsimha Reddy.Anti atherosclerotic effect of atorvastatin and clopidogrel alone and in combination in rats.Indian Journal of Experimental Biology, October 2008; Vol.46:698-703.
6. Karl-Heinz Diehl, Robin Hull, David Morton, Rudolf Pfister, YvonRabemampianina, David Smith, Jean-Marc Vidal and Cor van de Vorstenbosch, A Good Practice Guide to the Administration of Substances and Removal of Blood, Including Routes and Volumes.Journal of Applied Toxicology. 200121, 15–23.
7. Yuh-Ching Chou ,Yi-Kai Wanga, Min-JiCharng , Yune-Fang Ueng, Determination of serum atorvastatin concentrations in lipid controlling patients with and without myalgia syndrome. Journal of food and drug analysis, 2013; 21:147-153.
8. Janne T. Backman, HarriLuurila, MikkoNeuvonen and Pertti J. NeuvonenRifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites.Clinical Pharmacology & Therapeutics, August 2005; Volume 78, Issue 2 : 154–167.
9. Andrén L, Andreasson A, EggertsenR.Interaction between a commercially available St. John's wort product (Movina) and atorvastatin in patients with hypercholesterolemia.Europian Journal of Clinical pharmacology,2007;63(10):913-6.
10. Jonathan Bullman, Andrew Nicholls, Kevan Van Landingham, Richard Fleck, AlainVuong, James Miller, Sarah Alexander and John Messenheime, Effects of lamotrigine and phenytoin on the pharmacokinetics of atorvastatin in healthy volunteers. Epilepsia, 2011; 52(7):1351–1358.
Suresh D, Devde R, Reddy N Y, Rao V D, Khan I.A. Study of pharmacokinetic interaction of Carbamazepine with Atorvastatin in dyslipidemic rats. Perspectives in medical research 2016;4 (3):32-38.